Nanja van Geel1, Janny E Lommerts2, Marcel W Bekkenk2, Cecilia A C Prinsen3, Viktoria Eleftheriadou4, Alain Taieb5, Mauro Picardo6, Khaled Ezzedine7, Albert Wolkerstorfer2, Reinhart Speeckaert8. 1. Department of Dermatology, Ghent University Hospital, Ghent, France. Electronic address: Nanja.vangeel@UGent.be. 2. Department of Dermatology, University of Amsterdam and Netherlands Institute for Pigment Disorders, Amsterdam, The Netherlands. 3. VU University Medical Center, Department of Epidemiology and Biostatistics, EMGO Institute for Health and Care Research, Amsterdam, The Netherlands. 4. Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, United Kingdom. 5. National Reference Center for Rare Skin Diseases, Hôpital St-André, University Hospital Center of Bordeaux, Bordeaux, France. 6. San Gallicano Dermatology Institute, Via Elio Chianesi, Roma, Italy. 7. EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), UPE-Université Paris-Est, Service de Dermatologie, Hôpital Henri Mondor, Paris, France. 8. Department of Dermatology, Ghent University Hospital, Ghent, France.
Abstract
BACKGROUND: The Vitiligo Extent Score (VES) has recently been introduced as a physicians' score for the clinical assessment of the extent of vitiligo, but a good patient self-assessment score is lacking. OBJECTIVE: The objective is to develop and validate a simplified version of the VES as a patient-reported outcome measure (PROM). METHODS: After extensive pilot testing, patients were asked to score their vitiligo extent twice with an interval of 2 weeks using the Self Assessment Vitiligo Extent Score (SA-VES). The scores were compared with the physicians' evaluation (VES). RESULTS: The SA-VES demonstrated very good test-retest reliability (intraclass correlation = 0.948, 95% confidence interval [CI]: 0.911-0.970) that was not affected by age, skin type, or vitiligo distribution pattern. According to patients, this evaluation method was easy to use (22% very easy; 49% easy; 29% normal) and required <5 minutes in the majority of patients (73%, <5 minutes; 24%, 5-10 minutes; 2%, 10-15 minutes). Comparison of the SA-VES and the VES demonstrated excellent correlation (r = 0.986, P <.001). LIMITATIONS: Few patients had a dark skin type. CONCLUSION: The results demonstrate excellent reliability of the SA-VES and excellent correlation with its investigator-reported counterpart (VES). This patient-oriented evaluation method provides a useful tool for the assessment of vitiligo extent.
BACKGROUND: The Vitiligo Extent Score (VES) has recently been introduced as a physicians' score for the clinical assessment of the extent of vitiligo, but a good patient self-assessment score is lacking. OBJECTIVE: The objective is to develop and validate a simplified version of the VES as a patient-reported outcome measure (PROM). METHODS: After extensive pilot testing, patients were asked to score their vitiligo extent twice with an interval of 2 weeks using the Self Assessment Vitiligo Extent Score (SA-VES). The scores were compared with the physicians' evaluation (VES). RESULTS: The SA-VES demonstrated very good test-retest reliability (intraclass correlation = 0.948, 95% confidence interval [CI]: 0.911-0.970) that was not affected by age, skin type, or vitiligo distribution pattern. According to patients, this evaluation method was easy to use (22% very easy; 49% easy; 29% normal) and required <5 minutes in the majority of patients (73%, <5 minutes; 24%, 5-10 minutes; 2%, 10-15 minutes). Comparison of the SA-VES and the VES demonstrated excellent correlation (r = 0.986, P <.001). LIMITATIONS: Few patients had a dark skin type. CONCLUSION: The results demonstrate excellent reliability of the SA-VES and excellent correlation with its investigator-reported counterpart (VES). This patient-oriented evaluation method provides a useful tool for the assessment of vitiligo extent.
Authors: Nicoline F Post; Rosalie M Luiten; Albert Wolkerstorfer; Marcel W Bekkenk; Markus Böhm Journal: Exp Dermatol Date: 2021-06-17 Impact factor: 4.511
Authors: N van Geel; L Depaepe; V Vandaele; L Mertens; J Van Causenbroeck; S De Schepper; L Van Coile; A Van Reempts; A-S De Vos; J Papeleu; I Hoorens; D Mertens; A Wolkerstorfer; J E Lommerts; R Speeckaert Journal: J Eur Acad Dermatol Venereol Date: 2022-04-29 Impact factor: 9.228
Authors: N van Geel; S E Uitentuis; M Zuidgeest; A Wolkerstorfer; M W Bekkenk; C Moock; C Van Goethem; E Verlaeckt; C Smet; L Grine; R Speeckaert Journal: J Eur Acad Dermatol Venereol Date: 2020-09-01 Impact factor: 9.228